FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048767892> ?p ?o ?g. }

• W3048767892 endingPage "108" @default.
• W3048767892 startingPage "100" @default.
• W3048767892 abstract "Although neoadjuvant chemotherapy is associated with a survival advantage in pure urothelial, muscle invasive bladder cancer, the role of neoadjuvant chemotherapy is less clear in variant histology or urothelial carcinoma with divergent differentiation. We compared chemotherapy response and survival outcomes of patients with nonpure urothelial carcinoma histology who were managed with neoadjuvant chemotherapy followed by cystectomy vs cystectomy alone.We analyzed 768 patients with clinical muscle invasive bladder cancer (cT2-4N0M0) who were treated with cystectomy at a tertiary care center from 2007 to 2017. Patients were stratified by histology and treatment strategy. Adjusted logistic and Cox regression models were used to evaluate pathological downstaging, cancer specific survival and overall survival.The cohort consisted of 410 patients (53%) with pure urothelial carcinoma, 185 (24%) with urothelial carcinoma with divergent differentiation and 173 (23%) with variant histology. Overall, 314 patients (41%) received neoadjuvant chemotherapy prior to cystectomy. There were similar rates of complete (18% to 30%) and partial (37% to 46%) pathological downstaging with neoadjuvant chemotherapy across all histological subgroups (p=0.30 and p=0.40, respectively). However, while patients with pure urothelial carcinoma experienced an overall survival benefit (HR 0.71, 95% CI 0.51-0.98, p=0.0013) and those with variant histology experienced a cancer specific survival benefit (HR 0.55, 95% CI 0.30-0.99, p=0.0495) with neoadjuvant chemotherapy, patients with urothelial carcinoma with divergent differentiation did not experience overall or cancer specific survival benefits with the use of neoadjuvant chemotherapy prior to cystectomy.Among patients with muscle invasive bladder cancer those with nonpure urothelial carcinoma histology with variant histology achieved nearly equivalent response rates and survival benefits with the use of neoadjuvant chemotherapy as those with pure urothelial carcinoma, while patients with urothelial carcinoma with divergent differentiation experienced significantly worse survival outcomes regardless of the use of neoadjuvant chemotherapy prior to cystectomy." @default.
• W3048767892 created "2020-08-18" @default.
• W3048767892 creator A5000377318 @default.
• W3048767892 creator A5013683254 @default.
• W3048767892 creator A5014513676 @default.
• W3048767892 creator A5015862974 @default.
• W3048767892 creator A5016805354 @default.
• W3048767892 creator A5017475053 @default.
• W3048767892 creator A5045698437 @default.
• W3048767892 creator A5047859811 @default.
• W3048767892 creator A5054735116 @default.
• W3048767892 creator A5067587158 @default.
• W3048767892 creator A5071641697 @default.
• W3048767892 creator A5081688115 @default.
• W3048767892 creator A5084794080 @default.
• W3048767892 date "2021-01-01" @default.
• W3048767892 modified "2023-10-16" @default.
• W3048767892 title "Pathological and Survival Outcomes Associated with Variant Histology Bladder Cancers Managed by Cystectomy with or without Neoadjuvant Chemotherapy" @default.
• W3048767892 cites W1558385747 @default.
• W3048767892 cites W1581476904 @default.
• W3048767892 cites W1847493486 @default.
• W3048767892 cites W1956984982 @default.
• W3048767892 cites W1977780578 @default.
• W3048767892 cites W1984543160 @default.
• W3048767892 cites W1990301861 @default.
• W3048767892 cites W1990758318 @default.
• W3048767892 cites W2031339582 @default.
• W3048767892 cites W2039935691 @default.
• W3048767892 cites W2047283411 @default.
• W3048767892 cites W2073887720 @default.
• W3048767892 cites W2099144023 @default.
• W3048767892 cites W2124614719 @default.
• W3048767892 cites W2125506656 @default.
• W3048767892 cites W2163823502 @default.
• W3048767892 cites W2166453367 @default.
• W3048767892 cites W2569407814 @default.
• W3048767892 cites W2609787832 @default.
• W3048767892 cites W2737911811 @default.
• W3048767892 cites W2738951134 @default.
• W3048767892 cites W2884639138 @default.
• W3048767892 cites W2904555583 @default.
• W3048767892 cites W2914703659 @default.
• W3048767892 cites W2917350005 @default.
• W3048767892 cites W2991616458 @default.
• W3048767892 cites W3004971171 @default.
• W3048767892 cites W1998100539 @default.
• W3048767892 doi "https://doi.org/10.1097/ju.0000000000001325" @default.
• W3048767892 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7864376" @default.
• W3048767892 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32783489" @default.
• W3048767892 hasPublicationYear "2021" @default.
• W3048767892 type Work @default.
• W3048767892 sameAs 3048767892 @default.
• W3048767892 citedByCount "19" @default.
• W3048767892 countsByYear W30487678922021 @default.
• W3048767892 countsByYear W30487678922022 @default.
• W3048767892 countsByYear W30487678922023 @default.
• W3048767892 crossrefType "journal-article" @default.
• W3048767892 hasAuthorship W3048767892A5000377318 @default.
• W3048767892 hasAuthorship W3048767892A5013683254 @default.
• W3048767892 hasAuthorship W3048767892A5014513676 @default.
• W3048767892 hasAuthorship W3048767892A5015862974 @default.
• W3048767892 hasAuthorship W3048767892A5016805354 @default.
• W3048767892 hasAuthorship W3048767892A5017475053 @default.
• W3048767892 hasAuthorship W3048767892A5045698437 @default.
• W3048767892 hasAuthorship W3048767892A5047859811 @default.
• W3048767892 hasAuthorship W3048767892A5054735116 @default.
• W3048767892 hasAuthorship W3048767892A5067587158 @default.
• W3048767892 hasAuthorship W3048767892A5071641697 @default.
• W3048767892 hasAuthorship W3048767892A5081688115 @default.
• W3048767892 hasAuthorship W3048767892A5084794080 @default.
• W3048767892 hasBestOaLocation W30487678922 @default.
• W3048767892 hasConcept C121608353 @default.
• W3048767892 hasConcept C126322002 @default.
• W3048767892 hasConcept C126894567 @default.
• W3048767892 hasConcept C143998085 @default.
• W3048767892 hasConcept C207886595 @default.
• W3048767892 hasConcept C2775910329 @default.
• W3048767892 hasConcept C2776694085 @default.
• W3048767892 hasConcept C2777546739 @default.
• W3048767892 hasConcept C2778292576 @default.
• W3048767892 hasConcept C2780352672 @default.
• W3048767892 hasConcept C530470458 @default.
• W3048767892 hasConcept C57742111 @default.
• W3048767892 hasConcept C71924100 @default.
• W3048767892 hasConceptScore W3048767892C121608353 @default.
• W3048767892 hasConceptScore W3048767892C126322002 @default.
• W3048767892 hasConceptScore W3048767892C126894567 @default.
• W3048767892 hasConceptScore W3048767892C143998085 @default.
• W3048767892 hasConceptScore W3048767892C207886595 @default.
• W3048767892 hasConceptScore W3048767892C2775910329 @default.
• W3048767892 hasConceptScore W3048767892C2776694085 @default.
• W3048767892 hasConceptScore W3048767892C2777546739 @default.
• W3048767892 hasConceptScore W3048767892C2778292576 @default.
• W3048767892 hasConceptScore W3048767892C2780352672 @default.
• W3048767892 hasConceptScore W3048767892C530470458 @default.
• W3048767892 hasConceptScore W3048767892C57742111 @default.
• W3048767892 hasConceptScore W3048767892C71924100 @default.
• W3048767892 hasIssue "1" @default.

• next